AHA Scientific Sessions 2026 Late-Breaking Science — American Heart Association, Chicago

22 late-breaking presentations across 6 Late-Breaking Science sessions at AHA Scientific Sessions 2026 in Chicago, 7-9 November. Each trial includes PICO analysis, expert commentary, key results, and clinical implications.

AHA Scientific Sessions 2026 Late-Breaking Science Results — every trial's key result on one page

  1. ZEUS: Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS) — Prevention
  2. Lp(a)HORIZON: Effect of pelacarsen on cardiovascular outcomes in patients with elevated lipoprotein(a): primary results from the Lp(a)HORIZON trial — Lipids
  3. Lp(a)HORIZON Extended Analyses: Extended analyses of cardiovascular outcomes with pelacarsen treatment in the Lp(a)HORIZON trial — Lipids
  4. OCEANIC-STROKE: FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial — Stroke
  5. REDUCE: A randomized controlled trial of spironolactone-based blood pressure management after stroke (REDUCE) — Stroke
  6. OPTIMAL-Stroke: Intensive blood-pressure control for the prevention of major cardiovascular events in patients with prior stroke: the OPTIMAL-Stroke trial — Stroke
  7. STREAM: Discontinuing statins in multimorbid older adults without cardiovascular disease: a randomized non-inferiority clinical trial (STREAM) — Prevention
  8. OPTIMAL-DIABETES: Intensive blood pressure control for the prevention of major cardiovascular events in patients with type 2 diabetes: the OPTIMAL-DIABETES trial — Hypertension
  9. eZ-PAVE: Statin-ezetimibe combination therapy versus statin monotherapy in patients with atherosclerotic cardiovascular disease: pre-specified second randomization of the eZ-PAVE trial — Lipids
  10. Yoga-CaRe HF: Yoga-based cardiac rehabilitation in heart failure with reduced ejection fraction (Yoga-CaRe HF) — Heart Failure
  11. OptimPacing: Left bundle branch pacing versus right ventricular pacing for atrioventricular block: an international multi-center randomized controlled trial (OptimPacing) — Devices & Arrhythmias
  12. COAST-AF Randomized: Characterization of arrhythmia substrate to ablate persistent atrial fibrillation: the COAST-AF randomized trial — Atrial Fibrillation
  13. SUPERIOR: Sacubitril/valsartan for preventing recurrence of atrial fibrillation after catheter ablation in patients with hypertension: a multicenter, randomized controlled trial (SUPERIOR) — Atrial Fibrillation
  14. RACE-CARS: Randomized cluster evaluation of cardiac arrest systems (RACE-CARS) trial: primary results — Acute Cardiac Care
  15. TYDAL-TIMI 78: A randomized trial of ANGPTL4 inhibition with MAR001 in adults with elevated triglycerides and remnant cholesterol concentrations (TYDAL-TIMI 78) — Lipids
  16. CTX310: CRISPR-Cas9 gene editing therapy targeting ANGPTL3 for severe hypertriglyceridemia: results from a phase 1b trial (CTX310) — Lipids
  17. ATTAIN-OSA: Orforglipron for the treatment of obstructive sleep apnea: results from ATTAIN-OSA — Cardiometabolic
  18. SYNCHRONIZE-CVOT: Survodutide and cardiovascular outcomes in obesity: results from the SYNCHRONIZE-CVOT trial — Cardiometabolic
  19. WATCH-LV: Consumer smartwatch artificial intelligence-enabled electrocardiogram for left ventricular systolic dysfunction: cross-manufacturer validation and serial home monitoring (WATCH-LV) — Digital Health
  20. PROVAR+: AI-enabled tele-ECG identifies structural heart disease and prioritizes echocardiography in underserved populations: the PROVAR+ external validation study — Digital Health
  21. AI-Echo RCT: AI-assisted comprehensive echocardiographic interpretation: a blinded, randomized controlled trial — Imaging
  22. AI Plaque + FFR-CT: All-cause and cardiovascular mortality in the U.S.: risk stratification via integrated AI-enabled coronary plaque analysis and FFR-CT in over 269,000 patients (LIFE-AI Study) — Imaging